Biogen initiates phase 3 study of felzartamab for the treatment of late antibody-mediated rejection (amr) in kidney transplant patients

Cambridge, mass., march 11, 2025 (globe newswire) -- biogen inc. (nasdaq: biib) – announced the initiation of dosing in the global clinical study, transcend. the phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (amr). transcend is designed to enroll approximately 120 kidney transplant recipients with late amr.
AMR Ratings Summary
AMR Quant Ranking